Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.10.036 ◽

2006 ◽

Vol 101 (3) ◽

pp. 436-440 ◽

Cited By ~ 134

Author(s):

Maurie Markman ◽

John Blessing ◽

Stephen C. Rubin ◽

Joseph Connor ◽

Parviz Hanjani ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (A Gynecologic Oncology Group Study)

American Journal of Obstetrics and Gynecology ◽

10.1016/0002-9378(89)90507-3 ◽

1989 ◽

Vol 161 (2) ◽

pp. 309-312 ◽

Cited By ~ 110

Author(s):

Gregory P. Sutton ◽

John A. Blessing ◽

Neil Rosenshein ◽

Guy Photopulos ◽

Philip J. DiSaia

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.055 ◽

2015 ◽

Vol 137 ◽

pp. 24 ◽

Cited By ~ 2

Author(s):

K.N. Moore ◽

M. Sill ◽

M.E. Tenney ◽

C.J. Darus ◽

D. Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Angiopoietin 1

Get full-text (via PubEx)

A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/0090-8258(92)90055-n ◽

1992 ◽

Vol 44 (3) ◽

pp. 268-270 ◽

Cited By ~ 11

Author(s):

Allan J. Jacobs ◽

John A. Blessing ◽

Alan Munoz

Keyword(s):

Cervical Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Didemnin B ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79511-7 ◽

2010 ◽

Vol 2010 ◽

pp. 73-74

Author(s):

J.T. Thigpen

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Her2 Positive ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.05.016 ◽

2005 ◽

Vol 98 (2) ◽

pp. 294-298 ◽

Cited By ~ 27

Author(s):

Howard D. Homesley ◽

John A. Blessing ◽

Joel Sorosky ◽

Gary Reid ◽

Katherine Y. Look

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary A Gynecologic Oncology Group study

American Journal of Clinical Oncology ◽

10.1097/00000421-198406000-00012 ◽

1984 ◽

Vol 7 (3) ◽

pp. 261-264 ◽

Cited By ~ 1

Author(s):

J. Tate Thigpen ◽

John A. Blessing ◽

James C. Arseneau ◽

Howard D. Homesley

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Recurrent Carcinoma ◽

Carcinoma Of The Ovary

Get full-text (via PubEx)

Phase II Trial of Pyrazoloacridine in Patients with Persistent or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2001.6491 ◽

2002 ◽

Vol 84 (2) ◽

pp. 241-244 ◽

Cited By ~ 14

Author(s):

Steven C. Plaxe ◽

John A. Blessing ◽

Nader Husseinzadeh ◽

Kenneth D. Webster ◽

Janet S. Rader ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Get full-text (via PubEx)

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.08.027 ◽

2018 ◽

Vol 151 (2) ◽

pp. 257-263 ◽

Cited By ~ 8

Author(s):

William P. Tew ◽

Michael W. Sill ◽

Joan L. Walker ◽

Angeles Alvarez Secord ◽

Albert J. Bonebrake ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized Phase Ii

Get full-text (via PubEx)